| Literature DB >> 31727175 |
Yang Li1, Wei Wang2, Fan Yang1, Yanan Xu1, Chang Feng1, Yong Zhao3,4.
Abstract
Neutrophils have long been considered as cells playing a crucial role in the immune defence against invading pathogens. Accumulating evidence strongly supported the direct and indirect regulatory effects of neutrophils on adaptive immunity. Exogenous cytokines or cytokines produced in an autocrine manner as well as a cell-to-cell contact between neutrophils and T cells could induce the expression of MHC-II and costimulatory molecules on neutrophils, supporting that neutrophils may function as antigen-presenting cells (APCs) in respects of presenting antigens and activating T cells. In addition to the inflammatory roles, neutrophils also have the propensity and ability to suppress the immune response through different mechanisms. In this review, we will mainly highlight the heterogeneity and functional plasticity of neutrophils and the antigen-presenting capacity of different neutrophil subsets. We also discuss mechanisms relevant to the regulatory effects of neutrophils on adaptive immunity. Understanding how neutrophils modulate adaptive immunity may provide novel strategies and new therapeutic approaches for diseases associated with neutrophils.Entities:
Year: 2019 PMID: 31727175 PMCID: PMC6854633 DOI: 10.1186/s12964-019-0471-y
Source DB: PubMed Journal: Cell Commun Signal ISSN: 1478-811X Impact factor: 5.712
Neutrophils treated with different stimulations display different phenotypes and regulatory function on adaptive immunity
| Treatment/source/subsets | Characteristics | Regulation on adaptive immunity | Species | Refs |
|---|---|---|---|---|
| GM-CSF, IFN-γ, IL-3 | MHC-II, CD80, CD86, CD83 | Undetected | Human | [ |
| GM-CSF, IFN-γ | MHC-II, CD80, CD86 | Undetected | Human | [ |
| GM-CSF, IFN-γ, IL-4, TNF-α and M-CSF | Macrophage-like neutrophils with HLA-DR | Undetected | Human | [ |
| GM-CSF, IFN-γ or combination | MHC-II, CD80, CD86 and CD83 | To present peptide antigen to CD4+ T cells | Human | [ |
| GM-CSF + IL-4 + TNF-α | HLA-DR, HLR-DQ, CD80, CD86 and CD40 | Stimulate T cell proliferation | Human | [ |
| Patients with acute infection | CD83 | Undetected | Human | [ |
| Patients with chronic inflammatory diseases | MHC-II, CD80/86 | Undetected | Human | [ |
| Patients with Wegener’s granulomatosis | MHC-II, CD80/86 | Undetected | Human | [ |
| Peritoneal cavity after i.p. administration of glycogen | MHC-II | To present the lysozyme antigen to T cells | Mouse | [ |
| Peritoneal cavity after i.p. injection of Fusobacterium nucleatum | Undetected | Stimulate T cell proliferation | Mouse | [ |
| GM-CSF | MHC-II, CD11c, CD80, CD86 | To present antigens to CD4+ T cells | Mouse | [ |
N(IL-23) (IL-23-stimulated) | Th17 cytokines | Undetected | Mice | [ |
N(IL-33) (IL-33-stimulated) | Th9 cytokines | Undetected | Mice | [ |
N(LPS) (LPS-stimulated) | TNF-α, IL-6 | Undetected | Mice | [ |
| GM-CSF, IFN-γ, and TNF-α in sepsis patients | CD40, CD64, CD86 | Undetected | Human | [ |
| Synovial fluid of patients with RA, co-cultured with autologous T cells | MHC-II, CD14, CD64, CD83 | Undetected | Human | [ |
| Peritoneal cavity after TG injection, co-cultured with purified CD4+ T cells | MHC-II, CD86 | Present peptides to T cells; Stimulate T cell proliferation and cytokine production | Mice | [ |
| The inflamed colon in colitis mouse | MHC-II, CD86 | Stimulate T cell proliferation and cytokine production | Mice | [ |
CD49d+CD11b− N1 (from MRSA-resistant mice) | IL-12, CCL3, TLR2, TLR4, TLR5, TLR8 | Th1 response | Mice | [ |
CD49d−CD11b+ N2 (from MRSA- sensitive mice) | IL-10, IL-4, CCL2, TLR2, TLR4, TLR7, TLR9 | Th2 response | Mice | [ |
CD49d−CD11b− neutrophils (from naïve mice) | TLR2, TLR4, TLR9 | no chemokines and cytokines | Mice | [ |
N1 TAN (blockade of TGF-β in tumor microenvironment) | Immuno-activating cytokines and chemokines | anti-tumorigenic; increasing CD8+ T cell activation | Mice | [ |
N2 TAN (stimulated by TGF-β in tumor microenvironment) | Undetected | Pro-tumorigenic; decreasing CD8+ T cell activation | Mice | [ |
Parasite-primed (helminth infection) | IL-13, IL-33 | macrophage activation | Mice | [ |
NCs in spleen (infected by bacteria) | IL-12 | acting as APC-like cells | Mice | [ |
CD15interCD16inter NBH1 (microbes infection) | IL-21, BAFF, APRIL, CXCL12, CXCL13; NBH1 expresses higher CD27, CD40L, CD86, CD95 and MHC-II, than NBH2 | B cell activation | Mice | [ |
| CD15lowCD16low NBH2 in spleen (microbes infection) | IL-21, BAFF, APRIL, CXCL12, CXCL13; NBH2 expresses higher CD24 than NBH1 | B cell activation | Mice | [ |
Fig. 1The regulatory effects of neutrophils on adaptive immune cells. Neutrophils regulate the adaptive immunity in direct and indirect manners. Neutrophils can migrate to dLNs and regulate T cell activation. Neutrophils promote T cell response via secreting the chemokines that attract T cells to the site of inflammation. Neutrophils can deliver antigens to DCs and make DCs more effective initiators of naive CD4+ T cell activation. Neutrophils in the dLNs localizing close to B cells accelerate plasma cell generation and antibody production associated with BAFF. Neutrophils in the spleen induce immunoglobulin class switching, somatic hypermutation and antibody production by activating MZ B cells through the productions of cytokines BAFF, APRIL and IL-21. NETs are composed of nuclear components such as DNA and histones and are decorated by proteins such as MPO and neutrophil elastase. NETs produced by neutrophils impact adaptive immunity by influencing DC maturation. NETs-stimulated pDCs via TLR9 induce anti-neutrophil cytoplasmic antibody production and related autoimmunity